EW

SEC source: 0001225208-24-005886 · doc4.xml · derivative · entry 5

Zovighian Bernard J · CIK 0001665141 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,500

Underlying: Common Stock · 33,500 shares

Expires not disclosed

F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2027. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2027. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

SEC source: 0001225208-24-005886 · doc4.xml · derivative · entry 4

Zovighian Bernard J · CIK 0001665141 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 178,400

Underlying: Common Stock · 178,400 shares

Expires 2031-05-06

F2 · derivative.exercise_date: These options were granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

SEC source: 0001225208-24-005886 · doc4.xml · nonDerivative · entry 2

Zovighian Bernard J · CIK 0001665141 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,688.9005

SEC source: 0001225208-24-005886 · doc4.xml · nonDerivative · entry 1

Zovighian Bernard J · CIK 0001665141 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,335.9005

F1 · shares: These restricted stock units were granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

SEC source: 0001225208-24-005885 · doc4.xml · derivative · entry 5

Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,075

Underlying: Common Stock · 11,075 shares

Expires not disclosed

F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2027. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2027. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

SEC source: 0001225208-24-005885 · doc4.xml · derivative · entry 4

Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,500

Underlying: Common Stock · 65,500 shares

Expires 2031-05-06

F2 · derivative.exercise_date: These options were granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments.

SEC source: 0001225208-24-005885 · doc4.xml · nonDerivative · entry 2

Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,759

SEC source: 0001225208-24-005885 · doc4.xml · nonDerivative · entry 1

Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,549

F1 · shares: These restricted stock units were granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

SEC source: 0001225208-24-005884 · doc4.xml · derivative · entry 4

SELLERS ROBERT W.A. · CIK 0001600739 · SVP, Corporate Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,820

Underlying: Common Stock · 4,820 shares

Expires 2031-05-06

F2 · derivative.exercise_date: These options were granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments.

SEC source: 0001225208-24-005884 · doc4.xml · nonDerivative · entry 2

SELLERS ROBERT W.A. · CIK 0001600739 · SVP, Corporate Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,310.198

SEC source: 0001225208-24-005884 · doc4.xml · nonDerivative · entry 1

SELLERS ROBERT W.A. · CIK 0001600739 · SVP, Corporate Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,488.198

F1 · shares: These restricted stock units were granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

SEC source: 0001225208-24-005883 · doc4.xml · derivative · entry 3

Markowitz Wayne · CIK 0001991414 · GM & SVP, Surgical

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,350

Underlying: Common Stock · 3,350 shares

Expires not disclosed

F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2027. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2027. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

SEC source: 0001225208-24-005883 · doc4.xml · derivative · entry 2

Markowitz Wayne · CIK 0001991414 · GM & SVP, Surgical

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,800

Underlying: Common Stock · 17,800 shares

Expires 2031-05-06

F2 · derivative.exercise_date: These options were granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

SEC source: 0001225208-24-005883 · doc4.xml · nonDerivative · entry 1

Markowitz Wayne · CIK 0001991414 · GM & SVP, Surgical

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,648.5547

F1 · shares: These restricted stock units were granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

SEC source: 0001225208-24-005882 · doc4.xml · nonDerivative · entry 2

Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,992.4373

SEC source: 0001225208-24-005882 · doc4.xml · nonDerivative · entry 1

Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,601.4373

F1 · shares: These restricted stock units were granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

SEC source: 0001225208-24-005702 · doc4.xml · nonDerivative · entry 3

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 177,709.8055

SEC source: 0001225208-24-005743 · doc4.xml · nonDerivative · entry 4

Zovighian Bernard J · CIK 0001665141 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · 401(k)

Disclosed balance after: 3,267.6552

F2 · balance_after: Reflects shares represented on the most recent statement of the Issuer's 401(k) Plan Administrator.

SEC source: 0001225208-24-005707 · doc4.xml · derivative · entry 5

Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,465 shares

Expires 2028-05-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4.

SEC source: 0001225208-24-005707 · doc4.xml · nonDerivative · entry 3

Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,474

SEC source: 0001225208-24-005707 · doc4.xml · nonDerivative · entry 2

Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,905

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4.

F1 · price: On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4.

SEC source: 0001225208-24-005706 · doc4.xml · derivative · entry 4

Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,796 shares

Expires 2028-05-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4.

SEC source: 0001225208-24-005706 · doc4.xml · nonDerivative · entry 3

Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,576.4373

SEC source: 0001225208-24-005706 · doc4.xml · nonDerivative · entry 2

Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,018.4373

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4.

F1 · price: On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4.

SEC source: 0001225208-24-005705 · doc4.xml · nonDerivative · entry 2

SELLERS ROBERT W.A. · CIK 0001600739 · SVP, Corporate Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,043.198

SEC source: 0001225208-24-005704 · doc4.xml · nonDerivative · entry 2

Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,915.7443

SEC source: 0001225208-24-005702 · doc4.xml · derivative · entry 4

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,157 shares

Expires 2028-05-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4.

SEC source: 0001225208-24-005702 · doc4.xml · nonDerivative · entry 2

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 177,968.8055

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4.

F1 · price: On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4.

SEC source: 0001225208-24-005703 · doc4.xml · derivative · entry 5

Wood Larry L · CIK 0001440660 · Global President TAVR & Surg

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,675 shares

Expires 2028-05-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4.

SEC source: 0001225208-24-005703 · doc4.xml · nonDerivative · entry 3

Wood Larry L · CIK 0001440660 · Global President TAVR & Surg

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 216,480.739

SEC source: 0001225208-24-005703 · doc4.xml · nonDerivative · entry 2

Wood Larry L · CIK 0001440660 · Global President TAVR & Surg

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 220,021.739

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4.

F1 · price: On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4.

SEC source: 0001225208-24-005701 · doc4.xml · derivative · entry 4

Chopra Daveen · CIK 0001740963 · CVP, TMTT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,713 shares

Expires 2028-05-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4.

SEC source: 0001225208-24-005701 · doc4.xml · nonDerivative · entry 3

Chopra Daveen · CIK 0001740963 · CVP, TMTT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,851

SEC source: 0001225208-24-005701 · doc4.xml · nonDerivative · entry 2

Chopra Daveen · CIK 0001740963 · CVP, TMTT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,172

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4.

F1 · price: On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4.

SEC source: 0001225208-24-005700 · doc4.xml · derivative · entry 6

BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,855 shares

Expires 2028-05-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4.

SEC source: 0001225208-24-005700 · doc4.xml · nonDerivative · entry 3

BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,668.7184

SEC source: 0001225208-24-005700 · doc4.xml · nonDerivative · entry 2

BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,143.7184

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4.

F1 · price: On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4.

SEC source: 0001225208-24-005743 · doc4.xml · derivative · entry 5

Zovighian Bernard J · CIK 0001665141 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,265 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4.

F1 · derivative.expiration_date: On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4.

SEC source: 0001225208-24-005743 · doc4.xml · nonDerivative · entry 3

Zovighian Bernard J · CIK 0001665141 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,835.9005

SEC source: 0001225208-24-005743 · doc4.xml · nonDerivative · entry 2

Zovighian Bernard J · CIK 0001665141 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,553.9005

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4.

F1 · price: On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4.

SEC source: 0001225208-24-005707 · doc4.xml · nonDerivative · entry 1

Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,440

SEC source: 0001225208-24-005706 · doc4.xml · nonDerivative · entry 1

Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,222.4373

SEC source: 0001225208-24-005705 · doc4.xml · nonDerivative · entry 1

SELLERS ROBERT W.A. · CIK 0001600739 · SVP, Corporate Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,163.198

SEC source: 0001225208-24-005704 · doc4.xml · nonDerivative · entry 1

Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,206.7443

SEC source: 0001225208-24-005702 · doc4.xml · nonDerivative · entry 1

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 173,811.8055

SEC source: 0001225208-24-005703 · doc4.xml · nonDerivative · entry 1

Wood Larry L · CIK 0001440660 · Global President TAVR & Surg

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 213,346.739

SEC source: 0001225208-24-005701 · doc4.xml · nonDerivative · entry 1

Chopra Daveen · CIK 0001740963 · CVP, TMTT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,459

SEC source: 0001225208-24-005700 · doc4.xml · nonDerivative · entry 1

BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,288.7184

SEC source: 0001225208-24-005743 · doc4.xml · nonDerivative · entry 1

Zovighian Bernard J · CIK 0001665141 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,288.9005

SEC source: 0001225208-24-005500 · doc4.xml · derivative · entry 5

MUSSALLEM MICHAEL A · CIK 0001204551 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 29,350 shares

Expires 2024-05-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.